{"id":56102,"date":"2024-02-07T05:53:12","date_gmt":"2024-02-07T05:53:12","guid":{"rendered":"https:\/\/medsname.com\/lariago-ds\/"},"modified":"2026-04-30T10:24:40","modified_gmt":"2026-04-30T10:24:40","slug":"lariago-ds","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/lariago-ds\/","title":{"rendered":"Lariago DS"},"content":{"rendered":"

<\/p>\n

\n

Snelle antwoord<\/h3>\n

Lariago DS<\/strong> bevat chloroquine phosphate 500 mg base equivalent<\/strong> (Ipca Laboratories). It treats chloroquine-sensitive malaria<\/strong> caused by P. falciparum<\/em>, P. vivax<\/em>, P. ovale<\/em>, en P. malariae<\/em>, and is also used for the prevention and treatment of extra-intestinal amoebiasis<\/strong>. Most modern endemic regions have widespread chloroquine resistance<\/strong> (sub-Saharan Africa, India, Southeast Asia, Amazon basin) \u2014 chloroquine is NOT appropriate prophylaxis for those destinations. Acute treatment dose: 1 g loading \u2192 500 mg at 6 \/ 24 \/ 48 h. Prophylaxis (chloroquine-sensitive areas only): 500 mg once weekly starting 1\u20132 weeks before travel, continued for 4 weeks after return. Take with food. Mandatory baseline + annual ophthalmology screening after 5 years of continuous use.<\/strong><\/p>\n<\/div>\n

\ud83c\udfed WHO-GMP certified manufacturer<\/strong>  \u00b7  \ud83d\udce6 Discreet packaging<\/strong>  \u00b7  \ud83c\udf0d Worldwide shipping<\/strong>  \u00b7  \u2b50 1.400+ klantbeoordelingen<\/a><\/strong><\/div>\n

\ud83d\udee1\ufe0f Every order is covered by our Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days we ship a free replacement on EMS or ITPS courier.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Lariago DS is sourced from a WHO-GMP certified manufacturer and shipped worldwide in discreet packaging. Every order is backed by our Reshipment Assurance Policy<\/a> and supported by our 1.400+ klantbeoordelingen<\/a>. Worldwide shipping with no prescription paperwork.<\/p>\n

About Lariago DS<\/h2>\n

Lariago DS is a 500 mg chloroquine phosphate tablet manufactured by Ipca Laboratories under WHO-GMP certified conditions. Chloroquine is a 4-aminoquinoline antimalarial \u2014 first synthesised in 1934 and the cornerstone of malaria treatment for most of the second half of the 20th century, before resistance emerged in P. falciparum during the 1960s. It remains effective in the few remaining chloroquine-sensitive regions and is on the WHO Essential Medicines list.<\/p>\n

Resistance map \u2014 read before purchase.<\/strong> Chloroquine is no longer effective against P. falciparum in sub-Saharan Africa, India, Southeast Asia (Thailand, Cambodia, Vietnam, Myanmar, Laos), the Amazon basin (Brazil, Peru, Colombia, Venezuela, Bolivia, Guyana), Papua New Guinea, the Solomon Islands<\/strong>, and most other tropical destinations. Use mefloquine, doxycycline, or atovaquone-proguanil for those areas. Chloroquine remains effective in the few remaining chloroquine-sensitive areas: Mexico (areas west and north of the Panama Canal), parts of Central America (Belize, Guatemala highlands, Honduras, Nicaragua, Panama west of the canal), Hispaniola (Haiti, Dominican Republic), much of the Middle East<\/strong>, and selected Pacific destinations. Confirm current resistance pattern at CDC Yellow Book<\/a> before travel.<\/div>\n

How chloroquine works<\/h2>\n

The malaria parasite digests host haemoglobin inside an acidic food vacuole, releasing free haem (toxic to the parasite). Normally the parasite polymerises haem into inert haemozoin (malaria pigment). Chloroquine accumulates in the food vacuole because its weak-base nature traps it in acidic compartments, where it binds free haem and prevents polymerisation. Toxic free haem accumulates and kills the parasite. Chloroquine resistance arises from PfCRT (P. falciparum chloroquine-resistance transporter) mutations that pump chloroquine back out of the food vacuole.<\/p>\n

Half-life is 1\u20132 months \u2014 chloroquine accumulates in tissue and is released slowly. This is why prophylaxis is dosed weekly and continued for 4 weeks after exposure.<\/p>\n

Indicaties en dosering<\/h2>\n
\n\n\n\n\n\n\n\n\n\n
Indicatie<\/th>\nDose (in mg base)<\/th>\nOpmerkingen<\/th>\n<\/tr>\n<\/thead>\n
Chloroquine-sensitive malaria \u2014 acute treatment, adult<\/td>\n1 000 mg base loading \u2192 500 mg base at 6, 24, and 48 h (total 2 500 mg base over 48 h)<\/td>\nAdd primaquine for radical cure of P. vivax \/ P. ovale (after G6PD test).<\/td>\n<\/tr>\n
Chloroquine-sensitive malaria prophylaxis, adult<\/td>\n500 mg base once weekly<\/td>\nStart 1\u20132 weeks before travel; continue weekly during exposure; continue 4 weeks after return.<\/td>\n<\/tr>\n
Paediatric treatment<\/td>\n10 mg\/kg base loading \u2192 5 mg\/kg at 6, 24, 48 h<\/td>\nSame total over 48 h. Tablets can be crushed and mixed with food.<\/td>\n<\/tr>\n
Paediatric prophylaxis<\/td>\n5 mg\/kg base once weekly (max 500 mg)<\/td>\nSame start \/ continue \/ stop schedule as adults.<\/td>\n<\/tr>\n
Extra-intestinal amoebiasis (amoebic liver abscess)<\/td>\n1 g\/day for 2 days, then 500 mg\/day for 2\u20133 weeks<\/td>\nAdjunct to metronidazole.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
Strength conversion.<\/strong> Chloroquine phosphate 500 mg salt = ~ 300 mg chloroquine base. Lariago DS contains a higher per-tablet dose for simpler weekly prophylaxis dosing \u2014 most adults take 1 tablet weekly to reach the 500 mg-base prophylactic target. Read the label and verify with the prescribing information; many references quote chloroquine base, while tablets are labelled by salt strength.<\/div>\n
Retinal-toxicity red-box.<\/strong> Like hydroxychloroquine, chloroquine accumulates in retinal pigment epithelium with chronic use. Risk of bull’s-eye maculopathy is HIGHER with chloroquine than with hydroxychloroquine<\/strong>. Long-term users (autoimmune disease, prophylaxis > 5 years) require baseline ophthalmology assessment + annual screening from year 5 with spectral-domain OCT, automated visual field 10-2, and fundus autofluorescence. Acute treatment courses (a few days) carry no significant retinal risk.<\/div>\n
G6PD note.<\/strong> Chloroquine has a much lower haemolysis signal than primaquine but case reports exist in severe G6PD deficiency. If giving chloroquine for prolonged periods to a known G6PD-deficient patient, monitor for haemolysis.<\/div>\n

Bijwerkingen<\/h2>\n